MX2023004538A - Compuestos y metodos para el tratamiento de trastornos oculares. - Google Patents
Compuestos y metodos para el tratamiento de trastornos oculares.Info
- Publication number
- MX2023004538A MX2023004538A MX2023004538A MX2023004538A MX2023004538A MX 2023004538 A MX2023004538 A MX 2023004538A MX 2023004538 A MX2023004538 A MX 2023004538A MX 2023004538 A MX2023004538 A MX 2023004538A MX 2023004538 A MX2023004538 A MX 2023004538A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- compositions
- treatment
- inflammatory
- compounds
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 title 1
- 208000030533 eye disease Diseases 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000001530 keratinolytic effect Effects 0.000 abstract 2
- 208000035473 Communicable disease Diseases 0.000 abstract 1
- 208000003556 Dry Eye Syndromes Diseases 0.000 abstract 1
- 229940124091 Keratolytic Drugs 0.000 abstract 1
- 206010065062 Meibomian gland dysfunction Diseases 0.000 abstract 1
- 230000003110 anti-inflammatory effect Effects 0.000 abstract 1
- 208000010217 blepharitis Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 210000000744 eyelid Anatomy 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 238000011200 topical administration Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Ophthalmology & Optometry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063094808P | 2020-10-21 | 2020-10-21 | |
| PCT/IB2021/000708 WO2022084739A1 (en) | 2020-10-21 | 2021-10-20 | Compounds and methods for the treatment of ocular disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023004538A true MX2023004538A (es) | 2023-06-19 |
Family
ID=81290138
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023004538A MX2023004538A (es) | 2020-10-21 | 2021-10-20 | Compuestos y metodos para el tratamiento de trastornos oculares. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230399317A1 (https=) |
| EP (1) | EP4232034A4 (https=) |
| JP (1) | JP2023546452A (https=) |
| KR (1) | KR20230110516A (https=) |
| CN (1) | CN116635032A (https=) |
| AU (1) | AU2021365530A1 (https=) |
| CA (1) | CA3196146A1 (https=) |
| IL (1) | IL302174A (https=) |
| MX (1) | MX2023004538A (https=) |
| WO (1) | WO2022084739A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024100454A2 (en) * | 2022-11-11 | 2024-05-16 | Azura Ophthalmics Ltd. | Composition and methods for improving signs and symptoms of ocular disorders |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2830024T3 (es) * | 2007-10-19 | 2021-06-02 | Novartis Ag | Composiciones y métodos para el tratamiento del edema macular |
| US20090257957A1 (en) * | 2008-04-15 | 2009-10-15 | John Burnier | Aerosolized LFA-1 antagonists for use in localized treatment of immune related disorders |
| BR112015014367B1 (pt) * | 2012-12-19 | 2022-11-22 | Novartis Ag | Composição inibidora de lfa-1, método para estabilizar a dita composição e uso da mesma para tratar uma doença ocular |
| US9463201B2 (en) * | 2014-10-19 | 2016-10-11 | M.G. Therapeutics Ltd | Compositions and methods for the treatment of meibomian gland dysfunction |
| US10688122B2 (en) * | 2015-09-28 | 2020-06-23 | Azura Ophthalmics Ltd. | Thiol and disulfide-containing agents for increasing meibomian gland lipid secretion |
| JP2019513775A (ja) * | 2016-04-19 | 2019-05-30 | アズーラ オフサルミックス エルティーディー． | 角化症の処置のための組成物 |
| EP3600272A4 (en) * | 2017-03-29 | 2021-01-13 | Azura Ophthalmics Ltd. | MEANS OF INCREASING LIPID SECRETION OF THE MEIBOMAN GLAND |
| WO2018212846A1 (en) * | 2017-05-19 | 2018-11-22 | Ocugen, Inc. | Ophthalmic compositions and methods of use |
| US20180333357A1 (en) * | 2017-05-19 | 2018-11-22 | Ocugen, Inc. | Nanoemulsions with anti-inflammatory activity |
| WO2019053607A1 (en) * | 2017-09-18 | 2019-03-21 | Glenmark Pharmaceuticals Limited | PROCESS FOR PREPARING LIFITEGRAST |
| US11001574B2 (en) * | 2017-11-17 | 2021-05-11 | Medichem S.A. | Process to obtain a tetrahydroisoquinoline derivative |
| WO2020212755A1 (en) * | 2019-04-18 | 2020-10-22 | Azura Ophthalmics Ltd. | Compounds and methods for the treatment of ocular disorders |
| JP7700045B2 (ja) * | 2019-04-18 | 2025-06-30 | アズーラ オフサルミックス エルティーディー． | 眼障害を処置するための化合物および方法 |
-
2021
- 2021-10-20 EP EP21882227.8A patent/EP4232034A4/en active Pending
- 2021-10-20 KR KR1020237016473A patent/KR20230110516A/ko active Pending
- 2021-10-20 IL IL302174A patent/IL302174A/en unknown
- 2021-10-20 WO PCT/IB2021/000708 patent/WO2022084739A1/en not_active Ceased
- 2021-10-20 JP JP2023524274A patent/JP2023546452A/ja active Pending
- 2021-10-20 AU AU2021365530A patent/AU2021365530A1/en not_active Abandoned
- 2021-10-20 MX MX2023004538A patent/MX2023004538A/es unknown
- 2021-10-20 CA CA3196146A patent/CA3196146A1/en active Pending
- 2021-10-20 US US18/033,055 patent/US20230399317A1/en active Pending
- 2021-10-20 CN CN202180086872.2A patent/CN116635032A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20230110516A (ko) | 2023-07-24 |
| CN116635032A (zh) | 2023-08-22 |
| AU2021365530A1 (en) | 2023-06-15 |
| EP4232034A4 (en) | 2024-12-04 |
| CA3196146A1 (en) | 2022-04-28 |
| JP2023546452A (ja) | 2023-11-02 |
| EP4232034A1 (en) | 2023-08-30 |
| AU2021365530A9 (en) | 2024-02-08 |
| WO2022084739A1 (en) | 2022-04-28 |
| IL302174A (en) | 2023-06-01 |
| US20230399317A1 (en) | 2023-12-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023004537A (es) | Compuestos y metodos para el tratamiento de trastornos oculares. | |
| Jassim et al. | Crosstalk between dysfunctional mitochondria and inflammation in glaucomatous neurodegeneration | |
| MX2016014634A (es) | Compuestos para el tratamiento de enfermedades y trastornos oftalmicos. | |
| MX2020003534A (es) | Composiciones oftalmicas que comprenden latanoprost para usarse en el tratamiento de las enfermedades oculares. | |
| EA201490163A1 (ru) | Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения | |
| EA201490277A1 (ru) | Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения | |
| CL2025001153A1 (es) | Agentes de arni para inhibir la expresión de la proteína quinasa dm1 (dmpk) | |
| MX2024003580A (es) | Metodos de tratamiento de enfermedades inflamatorias oculares. | |
| BR112021025701A2 (pt) | Formulações e métodos de parasiticida de isoxazolina para tratar blefarite | |
| AR033151A1 (es) | Agente para el tratamiento oftalmico topico de las enfermedades inflamatorias oculares | |
| MX2023004539A (es) | Compuestos y metodos para el tratamiento de trastornos oculares. | |
| MX2023004538A (es) | Compuestos y metodos para el tratamiento de trastornos oculares. | |
| MX2022013665A (es) | Composiciones y metodos heterodimeros para el tratamiento de trastornos oculares. | |
| Chen et al. | Nonsteroidal anti-inflammatory drugs for retinal neurodegenerative diseases | |
| EP3416617B1 (en) | Combination of an antiallergic agent with muscarinic antagonist and/or dopaminergic agonist for use in preventing/stopping of axial myopia in human | |
| MX2024012438A (es) | Inhibición de la histona deacetilasa 6 (hdac6) | |
| CL2020001426A1 (es) | Composición tópica oftálmica que comprende ácido dobesilico para tratar enfermedades del segmento posterior del ojo. | |
| AR092842A1 (es) | Tratamiento de enfermedades inflamatorias oculares usando laquinimod | |
| RU2020119228A (ru) | Соединения, композиции и способы лечения нарушений со стороны органа зрения и заболеваний кожи | |
| CL2025001428A1 (es) | Composiciones farmacéuticas para administración ocular | |
| RU2017111579A (ru) | Способы лечения и предотвращения заболеваний глаз, расстройств и патологических состояний меланином и аналогами, предшественниками и производными меланина | |
| MX2023010918A (es) | Metodos y composiciones para el tratamiento de enfermedades oculares. | |
| BR112023022561A2 (pt) | Métodos e composições para o tratamento de retinopatia diabética e condições relacionadas | |
| Ben Yahia et al. | Comparative effect of topical diclofenac and topical dexamethasone on anterior chamber flare and postoperative pain following rhegmatogenous retinal detachment surgery | |
| Delval et al. | Safety and efficacy of unpreserved timolol 0.1% gel in patients controlled by preserved latanoprost with signs of ocular intolerance |